TIDMGENI
RNS Number : 3857H
GENinCode PLC
06 April 2022
GENinCode Plc
("GENinCode" or the "Company")
Director appointment
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics
company focused on the prevention of cardiovascular disease,
announces the appointment to the Board of Felix Frueh , PhD
("Felix") as a Non-Executive Director.
Felix is a senior life sciences executive with in-depth
expertise in corporate, regulatory, and commercialisation
strategies, with a particular focus on precision medicine. He has
over 25 years of experience setting scientific and corporate
strategy in precision medicine, and has founded several start-ups
in the diagnostics and pharmaceutical sectors. He has worked in the
regulatory space for 18 years, including five years working with
the FDA.
In addition to his FDA career, Felix oversaw the creation and
operations of the world's largest next-generation, Clinical
Laboratory Improvement Amendments (CLIA)-certified, whole human
genome sequencing laboratory, as the Chief Scientific Officer of
Human Longevity (HLI). Prior to this, he served as President of
Medco Research Institute, Research Director for Pharmacogenetics of
Transgenomic, and Assistant Director of Protogene Laboratories. He
is Founder and Executive Partner of Opus Three, Co-Founder and
Partner of Profound Ventures, and Co-Founder and Chief Scientific
Officer of Selva Therapeutics. He also co-founded and formerly
served as the Chief Executive Officer of Intellos Health.
Felix received his PhD in biochemistry from the University of
Basel in Switzerland and completed postdoctoral fellowships at the
University of Basel and Stanford University. He has served as a
consultant, strategic advisor, and Board member to numerous
diagnostic, pharmaceutical, and other healthcare companies. He is
the author of more than 100 peer-reviewed articles, book chapters,
white papers, market analyses, strategies, and business plans.
Matthew Walls, CEO of GENinCode Plc commented : " We are
delighted that Felix is joining as a Non-Executive Director. Felix
can offer us invaluable insights into the FDA as we start to look
towards commericalisation in the US later this year, and his many
years of experience in key roles in the industry will be a huge
benefit to us. His depth of knowledge in precision medicine and
regulatory affairs is second-to-none and we are looking forward to
capitalising on his expertise."
Bill Rhodes, Non-Executive Chairman of GENinCode Plc, commented:
"Our goal is to improve the current standard of care in
cardiovascular disease worldwide through our unique portfolio of
products, and Felix has the experience and expertise to help us
achieve this. I am looking forward to working with him, as is the
entire GENincode team, and welcome him to the Board."
Felix Frueh , PhD added: "I am thrilled to have been asked to
join the Board of GENinCode at this critical stage. I have spent
most of my career in the precision medicine space and feel I can
add real value to the team."
Regulatory disclosures
The following information is disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies in
relation to Felix Wilhelm Frueh, aged 54:
Current Directorships Previous Directorships
Opus Three Partners LLC Intellos Health LLC
Selva Therapeutics Enterome SA
Bloom Science, Inc. Ariana Pharmaceuticals SA
AZCERT
As of the date of this announcement, Felix Frueh holds no
ordinary shares in the capital of the Company. Save as disclosed
above there are no additional disclosures to be made in accordance
with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.
For more information visit www.genincode.com
GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or
Anna Dunphy / Paul McManus / Louis Ashe-Jepson genincode@walbrookpr.com
About GENinCode
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United
States through GENinCode U.S. Inc and in Europe through GENinCode
S.L.U.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical algorithms and bioinformatics to provide advanced patient
risk assessment to predict disease onset.
About Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death
globally, taking an estimated 17.9 million lives each year. CVD is
a group of disorders of the heart and blood vessels and include
coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths
are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age.
The most important behavioural risk factors of heart disease and
stroke are unhealthy diet, physical inactivity, tobacco use and
harmful use of alcohol. The effects of behavioural risk factors may
show up in individuals as raised blood pressure, raised blood
glucose, raised blood lipids, and overweight and obesity. These
"intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke,
heart failure and other complications.
Cessation of tobacco use, reduction of salt in the diet, eating
more fruit and vegetables, regular physical activity and avoiding
harmful use of alcohol have been shown to reduce the risk of
cardiovascular disease. Health policies that create conducive
environments for making healthy choices affordable and available
are essential for motivating people to adopt and sustain healthy
behaviours.
Identifying those at highest risk of CVDs and ensuring they
receive appropriate treatment can prevent premature deaths. Access
to noncommunicable disease medicines and basic health technologies
in all primary health care facilities is essential to ensure that
those in need receive treatment and counselling.
CVD causes a quarter of all deaths in the UK and is the largest
cause of premature mortality in deprived areas and is the single
biggest area where the NHS can save lives over the next 10 years.
CVD is largely preventable, through lifestyle changes and a
combination of public health and NHS action on smoking and tobacco
addiction, obesity, tackling alcohol misuse and food
reformulation.
Genetic risk assessment can help early detection and treatment
of CVD to help patients live longer, healthier lives. Many people
are still living with undetected, high-risk conditions such as high
blood pressure, raised cholesterol, and atrial fibrillation (AF).
Progress continues in the NHS to identify and diagnose people
routinely knowing their 'ABC' (testing and monitoring of AF, Blood
pressure and Cholesterol) set out in the NHS 10 Year plan.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASSMFMIEESEDL
(END) Dow Jones Newswires
April 06, 2022 02:01 ET (06:01 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genincode (LSE:GENI)
Historical Stock Chart
From Apr 2023 to Apr 2024